Ellex gets CE Mark approval for 2RT laser treatment of early stage AMD

Ellex Medical Lasers Limited (ASX:ELX), a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that it has secured a CE Mark (Conformité Européenne) for its proprietary Retinal Rejuvenation Therapy (2RT™) laser treatment of early Age-Related Macular Degeneration (AMD).

The leading cause of blindness in the developed world, AMD is a chronic eye disease that can result in vision loss in the central field of vision, including blurred central vision or a blind spot.

There are no other approved treatments for the early form of AMD. Current treatment options are restricted to targeting the late form of the disease, referred to as Wet AMD, which only accounts for approximately 10-15% of all people who suffer from AMD. This represents a significant market opportunity for 2RT™.

“2RT is a laser treatment of early stage AMD. Unlike current treatments, which only target the late-stage complications associated with AMD, with 2RT we aim to treat the disease before complications set in.” commented Ellex CEO, Tom Spurling.

The CE Mark will allow the Company to move forward with a commercial program for 2RT in the treatment of early AMD and facilitates product sales in Europe, Australia, New Zealand, and in several South East Asian, Middle Eastern and South American countries.

“With the CE Mark now in place we will commence our commercial program with a limited roll-out of the 2RT laser to a number of key clinical sites. This is a necessary step in validating, and expanding upon, the clinical findings we so far have for 2RT, and will ultimately support a wider roll out of the product and future sales growth. ” said Mr. Spurling.

Source: http://www.ellex.com/